Defence Therapeutics Inc
CNSX:DTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Defence Therapeutics Inc
CNSX:DTC
|
CA |
Defence Therapeutics Inc
Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-05-07. The Company’s principal business activity is the development of a biological drug enhancer platform for biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The firm is engaged in developing the vaccines and antibody drug conjugates (ADC) products. Its Accum Technology platform provides drug delivery enhancements. The firm is focused on infectious disease and virus vaccine development by utilizing its platform for targeted drug delivery and treatments. Accum-T-DM1 is the Company’s product that is in preclinical stage.
Defence Therapeutics, Inc. engages in the research and development of anti-body drug conjugates. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-05-07. The Company’s principal business activity is the development of a biological drug enhancer platform for biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The firm is engaged in developing the vaccines and antibody drug conjugates (ADC) products. Its Accum Technology platform provides drug delivery enhancements. The firm is focused on infectious disease and virus vaccine development by utilizing its platform for targeted drug delivery and treatments. Accum-T-DM1 is the Company’s product that is in preclinical stage.
